PRimary Care Opioid Use Disorders Treatment (PROUD) Trial (PROUD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03407638|
Recruitment Status : Recruiting
First Posted : January 23, 2018
Last Update Posted : September 6, 2018
Effective treatment for opioid use disorders (OUDs) requires medications. Two medications for treating OUDs—buprenorphine and injectable naltrexone—can be prescribed in primary care (PC). However, despite the current opioid epidemic and expert recommendations that OUDs should be treated in PC, most PC clinics do not offer treatment for OUDs. This reflects a lack of consensus among health system leaders and clinicians that OUDs should be treated in PC.
The PRimary care Opioid Use Disorders treatment (PROUD) Trial is a pragmatic cluster-randomized, quality improvement trial that evaluates implementation of a team-based approach to PC supported by a full time nurse (the "PROUD intervention"). This type of team-based PC is often referred to as "collaborative care" for management of OUDs in PC, and this type of trial is often referred to as a Hybrid Type III implementation trial.
The trial is being conducted in 6 diverse health systems spanning 5 states (New York, Florida, Michigan, Texas, and Washington), with 2 PC clinics in each system randomized. One clinic is randomly selected to implement the PROUD intervention and the other continues usual PC (UPC).
The overall objective of the PROUD trial is to provide information to guide health system leaders who are faced with the decision of whether or not to treat OUDs in PC, by evaluating the benefits of implementing the PROUD intervention that integrates high quality OUD treatment (i.e. buprenorphine or injectable naltrexone) into the normal flow of PC.
The primary objective of the PROUD trial is to evaluate whether the PROUD intervention increases OUD treatment with buprenorphine or injectable naltrexone, documented in the electronic health records (EHRs) of PC patients, over a 2 year follow-up, as compared to UPC.
The primary hypothesis is that there will be a significant increase in the number of patient-days of medication treatment for OUDs documented in the EHR of PC patients in the 2 years after clinics are randomized to the PROUD intervention compared to PC clinics randomized to UPC. This implementation objective reflects whether the PROUD intervention increases initiation of and/or retention in OUD treatment, documented in EHRs within medical settings.
The main secondary objective is to test the hypothesis that PC patients with OUDs documented in their EHRs in the 3 years prior to randomization who receive care in PROUD intervention clinics, compared to those who receive care in UPC clinics, will have fewer days of acute care utilization (including urgent care, emergency department [ED] and hospital care) in the 2 years after randomization. This effectiveness objective assesses whether implementation of the MA Model improves patient outcomes.
|Condition or disease||Intervention/treatment||Phase|
|Opioid-use Disorder||Other: PROUD Intervention||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||175000 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Pragmatic Trial: Six health systems are participating in a pragmatic, cluster-randomized, quality improvement trial (hybrid Type III implementation trial). Each of the 6 health systems provided 2 PC clinics willing to be in the randomized controlled trial. Each health system will implement collaborative care for OUD treatment in one randomly selected PC clinic. All data used to evaluate primary and secondary outcomes are secondary data from the EHR or insurance claims.|
|Masking:||None (Open Label)|
Statistical analysts (biostatisticians) who analyze trial results will be masked for objectives 1 and 2.
Main analyses of the primary outcome will be conducted by the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN) Data and Statistics Center (DSC). The de-identified dataset provided to the DSC by the data management team at Kaiser Permanente Washington Health Research Institute will have the identity of the intervention and Usual Primary Care clinic at each site masked.
|Primary Purpose:||Health Services Research|
|Official Title:||PRimary Care Opioid Use Disorders Treatment (PROUD) Trial|
|Actual Study Start Date :||February 28, 2018|
|Estimated Primary Completion Date :||February 1, 2021|
|Estimated Study Completion Date :||February 1, 2021|
Active Comparator: PROUD Intervention
Primary care clinics randomized to the PROUD Intervention will implement the Massachusetts (MA) Model of collaborative care for opioids use disorders (OUDs). The PROUD trial provides financial support to cover the nurse case manager (NCM) salary and technical assistance for the duration of the study, but the health systems—not investigators—implement the MA Model as part of quality improvement, and the health system and its clinicians provide all clinical care.
Other: PROUD Intervention
The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
No Intervention: Usual Primary Care
Clinics randomized to usual primary care do not receive any resources or support from the study but are free to improve opioid use disorder (OUD) care in any way they choose.
- Patient-days of OUD medication treatment [ Time Frame: 2-year period post-randomization ]Clinic-level number of patient-days of OUD treatment with buprenorphine and injectable naltrexone documented in the EHR during the period from randomization until two years after, reported per 10,000 primary care patients in the clinic in the 2 years post-randomization.
- Acute care utilization [ Time Frame: 2-year period post-randomization ]Patient-level number of days of acute care utilization during the period from randomization until two years after, among patients with an OUD diagnosis documented in the EHR in the three years prior to randomization.
- Newly recognized OUDs [ Time Frame: 2 years after randomization ]Clinic-level number of patients with a new International Classification of Disease (ICD) code for OUD documented in the EHR during the period from randomization until two years after who did not have an OUD diagnosis documented in the EHR in the three years prior to randomization, reported per 10,000 primary care patients in the clinic in the 2 years post-randomization.
- Initiation of OUD treatment [ Time Frame: 2 years after randomization ]Clinic-level number of patients who initiate (1) buprenorphine or (2) injectable naltrexone with an OUD diagnosis as documented in the EHR during the period from randomization until two years after, reported per 10,000 primary care patients in the clinic in the 2 years post-randomization. Measure will be calculated for any initiation and separately for initiation of each type of medication.
- Retention in OUD treatment [ Time Frame: 2 years after randomization ]Clinic-level number of patients initiating OUD treatment during the period from randomization until two years after randomization as documented in the EHR, who also receive OUD treatment on 80% of days available after initiation, reported per 10,000 primary care patients in the clinic in the 2 years post-randomization.
- Urgent care or ED use [ Time Frame: 2 years after randomization ]Patient-level number of visits to urgent care or EDs during the period from randomization until two years after, among patients with an OUD diagnosis documented in the EHR in the three years prior to randomization.
- Inpatient Days hospitalized [ Time Frame: 2 years after randomization ]Patient-level number of days hospitalized during the period from randomization until two years after, among patients with an OUD diagnosis documented in the EHR in the three years prior to randomization.
- Naloxone prescribing [ Time Frame: 2 years after randomization ]Patient-level number of prescriptions of naloxone for overdose management in the period from randomization until two years after, among patients with an OUD diagnoses in the three years prior to randomization.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03407638
|Contact: Megan Addis||206-287-2052||CTN.PROUD.STUDY@ghc.org|
|Contact: Casey Luce||206-287-2972||CTN.PROUD.STUDY@ghc.org|
|United States, Florida|
|University of Miami Health System||Recruiting|
|Miami, Florida, United States, 33136|
|Contact: Ingrid Usaga, MSW 305-243-4355 firstname.lastname@example.org|
|Contact: Viviana Horigian, MD 305-243-4305 email@example.com|
|Principal Investigator: Viviana Horigian, MD|
|United States, Michigan|
|Henry Ford Health System||Recruiting|
|Detroit, Michigan, United States, 48202|
|Contact: Amy Loree, PhD 313-874-5452 firstname.lastname@example.org|
|Contact: Brian Ahmendani, PhD 313-874-5485 email@example.com|
|Principal Investigator: Jordan Braciszewski, PhD|
|United States, New York|
|Montefiore Medical Center||Recruiting|
|Bronx, New York, United States, 10467|
|Contact: Julia Arnsten, MD, MPH 718-920-6641 firstname.lastname@example.org|
|Contact: Chinazo Cunningham, MD, MS 718-920-4321 CCUNNING@montefiore.org|
|Principal Investigator: Julia Arnsten, MD, MPH|
|United States, Texas|
|Harris Health System||Recruiting|
|Houston, Texas, United States, 77054|
|Contact: Jennifer Lahue, MBA, BSN, RN 713-566-3840 Jennifer.Lahue@harrishealth.org|
|Contact: Angela Stotts, PhD 713-500-7590 Angela.L.Stotts@uth.tmc.edu|
|Principal Investigator: Mohammad Zare, MD, MS|
|United States, Washington|
|Kaiser Permanente Washington||Recruiting|
|Seattle, Washington, United States, 98112|
|Contact: Megan Addis, BA 206-287-2052 CTN.PROUD.STUDY@ghc.org|
|Contact: Casey Luce, MSPH 206-287-2972 CTN.PROUD.STUDY@ghc.org|
|Principal Investigator: Joseph Glass, PhD, MSW|
|MultiCare Health System||Recruiting|
|Tacoma, Washington, United States, 98405|
|Contact: Angela Silva, DBA 253-402-5263 email@example.com|
|Contact: Paul Amoroso, MD 253-403-5271 firstname.lastname@example.org|
|Principal Investigator: Mark Murphy, MD|
|Principal Investigator:||Katharine A Bradley, MD, MPH||Kaiser Permanente Washington|